{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:28:57Z","timestamp":1793896137633,"version":"4.8.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Zhejiang Key Research and Development Program","award":["2019C03042"],"award-info":[{"award-number":["2019C03042"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Omalizumab is a valuable alternative treatment for allergic bronchopulmonary aspergillosis (ABPA). The effectiveness and safety of this medication have not been confirmed. The main purpose of this study was to evaluate the effectiveness and safety of omalizumab for ABPA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study involved a retrospective chart review. The main indicators used were asthma control test (ACT) scores, lung function parameters, doses of corticosteroids, acute exacerbation, hospitalization rates, total serum immunoglobulin E (IgE) levels, and blood eosinophil counts. Related adverse events were also reviewed to evaluate the safety of omalizumab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fourteen patients with ABPA were included, of whom 10 (71%) concurrently had allergic rhinitis (AR). There were improvements in the mean percentages of the forced vital capacity, percentages of the forced expiratory volume in 1\u00a0s, and ACT score after omalizumab administration (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01, and <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01, respectively). After the initiation of omalizumab administration, the median corticosteroid dose, acute exacerbation rate, hospitalization rate, and mean blood eosinophil count decreased when compared with the baseline values (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01, and <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05, respectively). A reduction in the total serum IgE level was observed in patients with ABPA without AR compared with that in patients with AR (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). One patient reported a concurrent skin rash, which spontaneously resolved without medication.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>It is safe and effective to prescribe omalizumab to patients with ABPA, irrespective of whether they have AR. Dose adjustment of omalizumab is safe after disease control. The total serum IgE level might be a predictor of the effectiveness of omalizumab in patients without AR.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-023-02696-x","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T06:01:52Z","timestamp":1697176912000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effectiveness and safety of omalizumab in patients with allergic bronchopulmonary aspergillosis with or without allergic rhinitis: a retrospective chart review"],"prefix":"10.1186","volume":"23","author":[{"given":"Cuihong","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"key":"2696_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3109\/13693786.2012.738312","volume":"51","author":"DW Denning","year":"2013","unstructured":"Denning DW, Pleuvry A, Cole DC. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol. 2013;51:361\u201370.","journal-title":"Med Mycol"},{"key":"2696_CR2","first-page":"12","volume":"34","author":"YL Ma","year":"2011","unstructured":"Ma YL, Zhang WB, Yu B, Chen YW, Mu S, Cui YL. Prevalence of allergic bronchopulmonary aspergillosis in chinese patients with bronchial asthma. Chin J Tuberc Respir Dis. 2011;34:12.","journal-title":"Chin J Tuberc Respir Dis"},{"key":"2696_CR3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1159\/000507216","volume":"181","author":"K Tomomatsu","year":"2020","unstructured":"Tomomatsu K, Oguma T, Baba T, Toyoshima M, Komase Y, Taniguchi M, et al. Effectiveness and safety of omalizumab in patients with allergic bronchopulmonary aspergillosis complicated by chronic bacterial infection in the airways. Int Arch Allergy Immunol. 2020;181:499\u2013506.","journal-title":"Int Arch Allergy Immunol"},{"key":"2696_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jcf.2019.07.011","volume":"19","author":"A Koutsokera","year":"2020","unstructured":"Koutsokera A, Corriveau S, Sykes J, Coriati A, Cortes D, Vadas P, et al. Omalizumab for asthma and allergic bronchopulmonary aspergillosis in adults with cystic fibrosis. J Cyst Fibros. 2020;19:119\u201324.","journal-title":"J Cyst Fibros"},{"key":"2696_CR5","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","volume":"201","author":"ER Bleecker","year":"2020","unstructured":"Bleecker ER, Menzies-Gow AN, Price DB, Bourdin A, Sweet S, Martin AL, et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med. 2020;201:276\u201393.","journal-title":"Am J Respir Crit Care Med"},{"key":"2696_CR6","unstructured":"Full X, Prescribing information. Genentech. 2016;2017. https:\/\/www.gene.com\/download\/pdf\/xolair_prescribing.pdf. Accessed 12 Sep 2017."},{"key":"2696_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s12016-015-8490-y","volume":"50","author":"D El-Qutob","year":"2016","unstructured":"El-Qutob D. Off-label uses of omalizumab. Clin Rev Allergy Immunol. 2016;50:84\u201396.","journal-title":"Clin Rev Allergy Immunol"},{"key":"2696_CR8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jaip.2014.12.008","volume":"3","author":"AL Voskamp","year":"2015","unstructured":"Voskamp AL, Gillman A, Symons K, Sandrini A, Rolland JM, O\u2019Hehir RE, et al. Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract. 2015;3:192\u20139.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2696_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.rmed.2016.11.019","volume":"122","author":"JX Li","year":"2017","unstructured":"Li JX, Fan LC, Li MH, Cao WJ, Xu JF. Beneficial effects of omalizumab therapy in allergic bronchopulmonary aspergillosis: a synthesis review of published literature. Respir Med. 2017;122:33\u201342.","journal-title":"Respir Med"},{"key":"2696_CR10","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jaip.2022.12.012","volume":"11","author":"M Jin","year":"2013","unstructured":"Jin M, Douglass JA, Elborn JS, Agarwal R, Calhoun WJ, Lazarewicz S, et al. Omalizumab in allergic bronchopulmonary aspergillosis: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2013;11:896\u2013905.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2696_CR11","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/j.1398-9995.2011.02599.x","volume":"66","author":"I Tillie-Leblond","year":"2011","unstructured":"Tillie-Leblond I, Germaud P, Leroyer C, T\u00e9tu L, Girard F, Devouassoux G, et al. Allergic bronchopulmonary aspergillosis and omalizumab. Allergy. 2011;66:1254\u20136.","journal-title":"Allergy"},{"key":"2696_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.7326\/0003-4819-86-4-405","volume":"86","author":"M Rosenberg","year":"1977","unstructured":"Rosenberg M, Patterson R, Mintzer R, Cooper BJ, Roberts M, Harris KE. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med. 1977;86:405\u201314.","journal-title":"Ann Intern Med"},{"key":"2696_CR13","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2500\/aap.2015.36.3909","volume":"36","author":"\u00c3\u2013 Ayd\u0131n","year":"2015","unstructured":"Ayd\u0131n \u00c3\u2013, S\u00f6zener Z\u00c3\u2021, Soyyi\u011fit \u015e, Kendirlinan R, Gen\u00e7t\u00fcrk Z, M\u0131s\u0131rl\u0131gil Z, et al. Omalizumab in the treatment of allergic bronchopulmonary aspergillosis: one center\u2019s experience with 14 cases. Allergy Asthma Proc. 2015;36:493\u2013500.","journal-title":"Allergy Asthma Proc"},{"key":"2696_CR14","doi-asserted-by":"crossref","unstructured":"Albogami S. Use of biologic drugs for treatment of allergic bronchopulmonary aspergillosis. IJOPRS. 2021;5.","DOI":"10.19080\/IJOPRS.2021.05.555663"},{"key":"2696_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.rmed.2017.11.007","volume":"133","author":"C Perisson","year":"2017","unstructured":"Perisson C, Destruys L, Grenet D, Bassinet L, Derelle J, Sermet-Gaudelus I, et al. Omalizumab treatment for allergic bronchopulmonary aspergillosis in young patients with cystic fibrosis. Respir Med. 2017;133:12\u20135.","journal-title":"Respir Med"},{"key":"2696_CR16","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1016\/j.jaip.2020.05.055","volume":"8","author":"P Wark","year":"2020","unstructured":"Wark P, Hussaini S, Holder C, Powell H, Gibson P, Oldmeadow C. Omalizumab is an effective intervention in severe asthma with fungal sensitization. J Allergy Clin Immunol Pract. 2020;8:3428\u20133433e1.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2696_CR17","first-page":"CD003559","volume":"1","author":"R Normansell","year":"2014","unstructured":"Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;1:CD003559.","journal-title":"Cochrane Database Syst Rev"},{"key":"2696_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1067\/mai.2003.49","volume":"111","author":"J Corren","year":"2003","unstructured":"Corren J, Casale T, Deniz Y, Ashby M. A recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol. 2003;111:87\u201390.","journal-title":"J Allergy Clin Immunol"},{"key":"2696_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2500\/ar.2015.6.0128","volume":"6","author":"KT Beam","year":"2015","unstructured":"Beam KT, Coop CA. Steroid sparing effect of omalizumab in seropositive allergic bronchopulmonary aspergillosis. Allergy Rhinol (Providence). 2015;6:143\u20135.","journal-title":"Allergy Rhinol (Providence)"},{"key":"2696_CR20","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jaip.2014.03.010","volume":"2","author":"M Humbert","year":"2014","unstructured":"Humbert M, Busse W, Hanania NA, Lowe PJ, Canvin J, Erpenbeck VJ, et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract. 2014;2:525\u201336e1.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2696_CR21","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.chest.2018.01.005","volume":"153","author":"R Agarwal","year":"2018","unstructured":"Agarwal R, Dhooria S, Singh Sehgal I, Aggarwal AN, Garg M, Saikia B, et al. A randomized trial of itraconazole vs prednisolone in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Chest. 2018;153:656\u201364.","journal-title":"Chest"},{"key":"2696_CR22","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1183\/13993003.01475-2015","volume":"47","author":"R Agarwal","year":"2016","unstructured":"Agarwal R, Aggarwal AN, Dhooria S, Singh Sehgal I, Garg M, Saikia B, et al. A randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Eur Respir J. 2016;47:490\u20138.","journal-title":"Eur Respir J"},{"key":"2696_CR23","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1067\/mai.2003.1388","volume":"111","author":"PA Wark","year":"2003","unstructured":"Wark PA, Hensley MJ, Saltos N, Boyle MJ, Toneguzzi RC, Epid GD, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol. 2003;111:952\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"2696_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1183\/09059180.00004813","volume":"23","author":"I Singh Sehgal","year":"2014","unstructured":"Singh Sehgal I, Agarwal R. Pulse methylprednisolone in allergic bronchopulmonary aspergillosis exacerbations. Eur Respir Rev. 2014;23:149\u201352.","journal-title":"Eur Respir Rev"},{"key":"2696_CR25","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.5415\/apallergy.2018.8.e24","volume":"8","author":"K Asano","year":"2018","unstructured":"Asano K, Kamei K, Hebisawa A. Allergic bronchopulmonary mycosis - pathophysiology, histology, diagnosis, and treatment. Asia Pac Allergy. 2018;8:e24.","journal-title":"Asia Pac Allergy"},{"key":"2696_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1749-6632.2012.06810.x","volume":"272","author":"RB Moss","year":"2012","unstructured":"Moss RB. The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis. Ann N Y Acad Sci. 2012;272:49\u201357.","journal-title":"Ann N Y Acad Sci"},{"key":"2696_CR27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s15007-019-1783-3","volume":"28","author":"G B\u00f6lke","year":"2019","unstructured":"B\u00f6lke G, Church MK, Bergmann KC. Comparison of extended intervals and dose reduction of omalizumab for asthma control. Allergo J Int. 2019;28:16\u20139.","journal-title":"Allergo J Int"},{"key":"2696_CR28","first-page":"1764","volume":"261","author":"ET Korkmaz","year":"2022","unstructured":"Korkmaz ET, Ayd\u0131n O, Mungan D, Sin BA, Demirel YS, Bavbek S. Can dose reduction be made in patients with allergic bronchopulmonary aspergillosis receiving high-dose omalizumab treatment? Eur Ann Allergy Clin Immunol. 2022;261:1764\u20131489.","journal-title":"Eur Ann Allergy Clin Immunol"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02696-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-023-02696-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02696-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T13:10:09Z","timestamp":1700313009000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-023-02696-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2696"],"URL":"https:\/\/doi.org\/10.1186\/s12890-023-02696-x","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"assertion":[{"value":"7 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments were performed in accordance with relevant guidelines and regulations (such as the Declaration of Helsinki). This study was reviewed and approved by the Independent Ethical Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University on December 28th (Number: 2022\u2009\u2212\u20091151). Given the retrospective nature of this study, informed consent exemption was obtained for this study from Ethics Committee of the First Affiliated Hospital of Zhejiang University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"389"}}